Real‐world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45‐year period

Summary The prognostic landscape of multiple myeloma (MM) has evolved significantly over the last few decades. There are, however, few data measuring such improvement in real‐world patients. This study aimed to investigate trends in survival improvement over 45 years, and the associated clinical factors, in an unselected population of patients with MM. Between 1970 and 2015, 1 161 MM patients were included. Patients were classified into three calendar periods (1970–1984, 1985–1999, and 2000–2015), according to the treatment received; polychemotherapy, autologous stem cell transplantation, and novel drugs respectively. We analysed relative survival (RS) to accurately evaluate MM‐related death rates after excluding the mortality expected in the general population. RS at five years increased from 27% in 1970–1984 to 38% and 56% in the next two calendar periods respectively. The improvement to survival was greater in the younger population, but it was also observed in elderly patients and those with poor performance status and more advanced disease. Although myeloma is still a non‐curable disease, encouraging results have been observed in the last decades. Progress is expected to continue with the use of new generations of anti‐myeloma drugs, and will, hopefully, be documented in real‐world patients by the appropriate population‐based studies.